CTEs contain multiple domains, with the simplest form comprising a protein target for a CAR T cell, for example the CD19 extracellular domain, linked to an antibody fragment that binds to a second ...

The resulting CD19-CAR T-cells were specifically activated ... 5 × 10 6 CAR T-cells were lysed and 10 μg of protein were separated on a 10% polyacrylamide gel. After blotting, membranes ...

Sana revolutionizes treatments for diabetes, cancer, and autoimmune diseases. SANA has high cash burn and dilution risks. See ...

A key target for these therapies is a protein called CD19 found on the cancer cells.” However, in 28-68% of cases, the cancer cells lower or lose this CD19 marker, making treatments less effective.

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

A key target for these therapies is a protein called CD19 found on the cancer cells," said study author Jianjun Chen, Ph.D., in a news release. Chen is also the director of the Center for RNA ...

To accomplish this mission, Estrella’s lead product candidate, EB103, utilizes Eureka’s ARTEMIS ® technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias ...